Management of dermatoses with topical clobetasol propionate 0.025%

Maragondanahalli G. Gopala; Sidramappa R. Warad; Manas R. Puhan; Saurabh Agrawal; Sanjay J. Parbhani; Kavita Mehendiratta; Mahaveer P. Gupta; Farhana T. Taj; Vamja Chirag; Satish D. A.

doi:10.18203/2320-6012.ijrms20220525

Authors

Maragondanahalli G. Gopala Department of Dermatology, Sree Venkateshwara Skin Clinic, Bangalore, Karnataka, India
Sidramappa R. Warad Department of Dermatology, Best Skin Clinic, Bijapur, Karnataka, India
Manas R. Puhan Department of Dermatology, Niki Skin Care, Cuttack, Odisha, India
Saurabh Agrawal Department of Dermatology, Saurabh Agrawal Clinic, Bikaner, Rajasthan, India
Sanjay J. Parbhani Department of Dermatology, Jogad Skin and Laser Center, Parbhani, Maharashtra, India
Kavita Mehendiratta Department of Dermatology, Dr. Kavita Skin Clinic, Faridabad, Haryana, India
Mahaveer P. Gupta Department of Dermatology, Medical Center, Jaipur, Rajasthan, India
Farhana T. Taj Department of Dermatology, KLE Deemed University, JNMC Campus, Belagavi, Karnataka, India
Vamja Chirag Department of Dermatology, Kalarav Hospital, Amreli, Gujarat, India
Satish D. A. Department of Dermatology, Skin Cosmetic and ENT Care Center, Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20220525

Keywords:

Clobetasol propionate 0.025%, Topical corticosteroid, Plaque psoriasis, Psoriasis

Abstract

The development of topical corticosteroids (TC) has enabled effective treatment of many dermatoses. The main therapeutic activity of topical corticosteroids is their nonspecific anti-inflammatory effect that primarily seems to be a result of their action on the chemical mediators of inflammation. Topical corticosteroids have also been shown to be antimitotic. Corticosteroids also play a vital role in cellular signaling, immune function and protein regulation. Clobetasol propionate (CP) 0.025% is a prescription corticosteroid medicine, used to treat moderate to severe plaque psoriasis in patients 18 years of age and older. It is a class I specialized cream formulation, that is free of propylene glycol, short-chain alcohols (e.g. ethanol), and sorbitan sesquioleate, a sorbitol-based emulsifier which is a common contact allergen used in many topical corticosteroid formulations. This case series discusses about management of different dermatoses using Impoyz^TM (clobetasol propionate) cream 0.025%.

Metrics

Metrics Loading ...

References

Sterry W. Therapy with topical corticosteroids. Arch Dermatol Res. 1992;284(1):27-9.

Del Rosso Do JQ. Combination topical therapy for the treatment of psoriasis. J Drugs Dermatol. 2006;5(3):232-4.

Del Rosso JQ. Topical corticosteroid therapy for psoriasis—a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Sukarovska BG, Lipozencic J, Vrzogic P. Topical corticosteroids and corticosteroid sparing therapy in psoriasis management. Acta Med Croatica. 2007;61(4):375-81.

Impoyz TM (clobetasol propionate) Cream. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209483Orig1s000MedR.pdf. Accessed on 10 December 2021.